-
Something wrong with this record ?
Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis
J. Dostál, J. Brynda, L. Vaňková, SR. Zia, I. Pichová, O. Heidingsfeld, M. Lepšík
Language English Country Great Britain
Document type Journal Article
NLK
Directory of Open Access Journals
from 2017
PubMed Central
from 2017
Taylor & Francis Open Access
from 2002-01-01
Medline Complete (EBSCOhost)
from 2007-02-01
- MeSH
- Aspartic Acid Endopeptidases antagonists & inhibitors metabolism MeSH
- Candida parapsilosis enzymology MeSH
- Fungal Proteins antagonists & inhibitors metabolism MeSH
- Protease Inhibitors chemical synthesis chemistry pharmacology MeSH
- Models, Molecular MeSH
- Molecular Structure MeSH
- Peptidomimetics chemical synthesis chemistry pharmacology MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Publication type
- Journal Article MeSH
Pathogenic Candida albicans yeasts frequently cause infections in hospitals. Antifungal drugs lose effectiveness due to other Candida species and resistance. New medications are thus required. Secreted aspartic protease of C. parapsilosis (Sapp1p) is a promising target. We have thus solved the crystal structures of Sapp1p complexed to four peptidomimetic inhibitors. Three potent inhibitors (Ki: 0.1, 0.4, 6.6 nM) resembled pepstatin A (Ki: 0.3 nM), a general aspartic protease inhibitor, in terms of their interactions with Sapp1p. However, the weaker inhibitor (Ki: 14.6 nM) formed fewer nonpolar contacts with Sapp1p, similarly to the smaller HIV protease inhibitor ritonavir (Ki: 1.9 µM), which, moreover, formed fewer H-bonds. The analyses have revealed the structural determinants of the subnanomolar inhibition of C. parapsilosis aspartic protease. Because of the high similarity between Saps from different Candida species, these results can further be used for the design of potent and specific Sap inhibitor-based antimycotic drugs.
Department of Biochemistry Faculty of Science Charles University Prague Prague Czech Republic
Department of Chemistry University of Karachi Karachi Pakistan
Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024850
- 003
- CZ-PrNML
- 005
- 20211026134319.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14756366.2021.1906664 $2 doi
- 035 __
- $a (PubMed)33843395
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dostál, Jiří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis / $c J. Dostál, J. Brynda, L. Vaňková, SR. Zia, I. Pichová, O. Heidingsfeld, M. Lepšík
- 520 9_
- $a Pathogenic Candida albicans yeasts frequently cause infections in hospitals. Antifungal drugs lose effectiveness due to other Candida species and resistance. New medications are thus required. Secreted aspartic protease of C. parapsilosis (Sapp1p) is a promising target. We have thus solved the crystal structures of Sapp1p complexed to four peptidomimetic inhibitors. Three potent inhibitors (Ki: 0.1, 0.4, 6.6 nM) resembled pepstatin A (Ki: 0.3 nM), a general aspartic protease inhibitor, in terms of their interactions with Sapp1p. However, the weaker inhibitor (Ki: 14.6 nM) formed fewer nonpolar contacts with Sapp1p, similarly to the smaller HIV protease inhibitor ritonavir (Ki: 1.9 µM), which, moreover, formed fewer H-bonds. The analyses have revealed the structural determinants of the subnanomolar inhibition of C. parapsilosis aspartic protease. Because of the high similarity between Saps from different Candida species, these results can further be used for the design of potent and specific Sap inhibitor-based antimycotic drugs.
- 650 _2
- $a aspartátové endopeptidasy $x antagonisté a inhibitory $x metabolismus $7 D016282
- 650 _2
- $a Candida parapsilosis $x enzymologie $7 D000074429
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a fungální proteiny $x antagonisté a inhibitory $x metabolismus $7 D005656
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a peptidomimetika $x chemická syntéza $x chemie $x farmakologie $7 D057786
- 650 _2
- $a inhibitory proteas $x chemická syntéza $x chemie $x farmakologie $7 D011480
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brynda, Jiří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Vaňková, Lucie $u Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Vestec, Czech Republic
- 700 1_
- $a Zia, Syeda Rehana $u Department of Chemistry, University of Karachi, Karachi, Pakistan
- 700 1_
- $a Pichová, Iva $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Heidingsfeld, Olga $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Lepšík, Martin $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
- 773 0_
- $w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 36, č. 1 (2021), s. 914-921
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33843395 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134324 $b ABA008
- 999 __
- $a ok $b bmc $g 1714084 $s 1145357
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 36 $c 1 $d 914-921 $e - $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
- LZP __
- $a Pubmed-20211013